Loading clinical trials...
Loading clinical trials...
A Phase II Study of Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma
Conditions
Interventions
avelumab
Locations
1
South Korea
81, Irwon-ro, Gangnam-gu, Seoul, Republic of Korea
Seoul, South Korea
Start Date
January 16, 2018
Primary Completion Date
January 30, 2022
Completion Date
March 30, 2022
Last Updated
September 24, 2021
NCT02859402
NCT03049449
NCT03646422
NCT02878278
Lead Sponsor
Samsung Medical Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions